The identification of transcription factors to induce pluripotency directly in somatic cells has given researchers a unique platform on which to dissect the mechanisms underlying epigenetic reprogramming. In addition, induced pluripotent stem (iPS) cells have enabled the derivation of patient-specific cells for the study and potential treatment of a variety of diseases. Here, we discuss recent discoveries in the reprogramming field including work from our own laboratory.
Reprogramming denotes the experimentally induced dedifferentiation of somatic cells into pluripotent cells, and pluripotency defines the ability of cells to give rise to all embryonic cell types including the germ line. Two major aims of reprogramming research are to understand the underlying mechanims at a biochemical level and to generate custom-tailored cells for studying and treating degenerative diseases. Experiments in mice have shown that iPS cells can indeed alleviate the disease phenotypes of sickle cell anemia (Hanna et al. 2007 ) and Parkinson's disease (Wernig et al. 2008b) . This, and the recent derivation of patient-specifc iPS cell lines from 11 different genetic disorders (Dimos et al. 2008; Park et al. 2008a) , demonstrates the potential utility of reprogramming research in a therapeutic setting.
Several different approaches have been developed to study the reprogramming of somatic cells into pluripotent cells, including nuclear transfer (NT), cell fusion, and direct reprogramming (Fig. 1) . During NT, the nucleus of a somatic cell is injected into an enucleated oocyte, which then develops into a cloned embryo. When transferred into a recipient female, the cloned embryo can develop into a live animal (so-called reproductive cloning) (Fig. 1A ) (Wilmut et al. 1997; Wakayama et al. 1998) . When explanted in vitro, NT-derived embryonic stem (ES) cells can be derived, which may be useful for custom-tailored cell therapy (so-called therapeutic cloning) (Rideout et al. 2002) . The process of NT is extremely inefficient (on average, only 1-3% of cloned blastocysts develop to term), and many of the cloned animals are abnormal, likely due to faulty epigenetic reprogramming of the genome (Hochedlinger and Jaenisch 2002b) . Interestingly, the derivation of ES cells from cloned blastocysts seems to select for fully reprogrammed cells because NT ES cells are molecularly and functionally indistinguishable from fertilization-derived ES cells, including their ability to give rise to entirely ES-cell-derived mice (Brambrink et al. 2006) . Thus, the abnormalities seen in cloned animals should not impede the therapeutic use of NT technology. However, ethical and legal constraints surrounding NT make alternative approaches to reprogramming desirable. Moreover, NT does not provide sufficient amounts of material to biochemically dissect the process of reprogramming.
An alternative approach to studying reprogramming is cell fusion, which involves the fusion of somatic cells with ES cells, thus generating pluripotent hybrids in which the somatic genome acquires epigenetic marks of ES cells (Fig. 1B) (Tada et al. 2001; Cowan et al. 2005) . Cell fusion is also quite inefficient, making it difficult to perform biochemical analyses. Nevertheless, cell fusion has been helpful in determining the effects of individual genes on reprogramming efficiency. For example, overexpression of the transcription factor Nanog in ES cells has been shown to result in an up to 200-fold increase in the number of reprogrammed hybrids upon fusion with neural stem cells (NSCs) (Silva et al. 2006 ). Cell fusion is not a viable approach in cell therapy, however, because the genomes of two different individuals are combined in hybrid cells, resulting in tetraploid cells that are prone to chromosomal abnormalities (Fujiwara et al. 2005) . Cell-fusion experiments indicated that ES cells, like oocytes, must contain factors that mediate reprogramming to pluripotency and that these molecules should be identifiable to directly reprogram somatic cells into a pluripotent state (Fig. 1C) . This notion prompted Yamanaka and colleagues to identify genes that are predominantly expressed in ES cells (Mitsui et al. 2003) and test the effect of their overexpression on somatic cells (Takahashi and Yamanaka 2006) . Indeed, they identified four transcription factors, Oct4, Sox2, Klf4, and c-Myc, out of an initial group of 24 candidate genes, which when overexpressed in fibroblasts, gave rise to pluripotent cells called iPS cells (Fig. 2) (Takahashi and Yamanaka 2006) . This chapter is aimed at summarizing the current knowledge on iPS cell research with an emphasis on work from our laboratory.
TRANSCRIPTION-FACTOR-INDUCED REPROGRAMMING
Previous work had indicated that individual transcription factors, when overexpressed or deleted, could induce cell-fate changes in somatic cells. Classical experiments in the 1980s showed that overexpression of the myogenic transcription factor MyoD was sufficient to convert fibroblasts into myogenic cells (Davis et al. 1987) . Similarly, elimination of Pax5 from B cells results in their dedifferentiation into progenitors that can give rise to multiple hematopoietic lineages (Nutt et al. 1999) , and overexpression of the transcription factor CEBPα has been shown to reprogram B and T cells into macrophages (Xie et al. 2004; Laiosa et al. 2006) . Together, these experiments provided the rationale for attempts to reprogram somatic cells directly into iPS cells.
iPS cells were initially obtained using drug selection for the ES-cell-specific, but nonessential, gene Fbx15 (Takahashi and Yamanaka 2006) . These first-generation iPS cells were similar but not identical to ES cells. They appeared to be transcriptionally and epigenetically intermediate between ES cells and fibroblasts, and although they did give rise to teratomas, they could not support the development of viable mice. Subsequent studies, however, showed that identifying iPS cells based on drug selection for the ES-cell-specific genes Oct4 or Nanog (Maherali et al. 2007; Okita et al. 2007; Wernig et al. 2007) , or simply based on morphological criteria alone (Blelloch et al. 2007; Maherali et al. 2007; Meissner et al. 2007) , was sufficient to generate iPS cells that were highly similar to ES cells (Fig. 2) . At the molecular level, iPS cells showed demethylation of the Oct4 and Nanog promoter regions and transcriptional patterns akin to ES cells (Maherali et al. 2007; Okita et al. 2007; Wernig et al. 2007 ). Global analysis of histone methylation patterns including histone H3 lysine 4 (K4) and H3 lysine 27 (K27) methylation indicated that iPS cells were indistinguishable from ES cells (Maherali et al. 2007 ). In addition, the somatically silenced X chromosome in female cells became reactivated and underwent random inactivation upon differentiation (Maherali et al. 2007 ), similar to ES cells derived by NT from female somatic cells (Eggan et al. 2000) . At the functional level, iPS cells produced viable chimeras that showed contribution to the germ line (Maherali et al. 2007; Okita et al. 2007; Wernig et al. 2007 ) and even supported the development of fetuses that were derived entirely from iPS cells Hanna et al. 2008; Kim et al. 2008) .
iPS cell have since been generated from multiple tissues, including blood, liver, stomach, pancreas, brain, skin, and adrenals ( Fig. 2) (Aoi et al. 2008; Eminli et al. 2008; Hanna et al. 2008; Kim et al. 2008; Stadtfeld et al. 2008a; Wernig et al. 2008a) . Moreover, human fibroblasts (Takahashi et al. 2007; Yu et al. 2007; Lowry et al. 2008; Maherali et al. 2008; Park et al. 2008b ) and keratinocytes (Maherali et al. 2008 ) have been converted into iPS cells by the same or a different combination of factors including OCT4, SOX2, LIN28, and NANOG. These results suggest that in vitro reprogramming is a universal process that functions in cell types derived from all three germ layers and in different species. However, the mechanisms underlying reprogramming remain largely unknown.
MOLECULAR CORNERSTONES OF DIRECT REPROGRAMMING
In vitro reprogramming is a gradual process that takes between 1 and 2 weeks in murine fibroblasts to generate pluripotent cells from somatic cells (Takahashi and Yamanaka 2006; Maherali et al. 2007; Okita et al. 2007; Wernig et al. 2007 ). To dissect the mechanism of reprogramming, it has been informative to study partially reprogrammed cells that have failed to silence the retroviral transgenes and regain expression of many important pluripotency regulators. Partially reprogrammed cells may have been generated when Fbx15 selection was initially used to identify iPS cells (Takahashi and Yamanaka 2006) and are frequently obtained when morphological 
ing and plating of these rare intermediate cell populations result in a significant increase in the number of successfully reprogrammed iPS colonies, thus validating the functional importance of the identified biomarkers (Stadtfeld et al. 2008b) . The observation that somatic markers are downregulated before progressing into a pluripotent state further supports the notion that silencing of cell-type-specific programs is an important initial step toward reestablishing pluripotency. It also suggests that the differentiation state of the starting cell may affect the efficiency and kinetics of in vitro reprogramming.
EFFECT OF CELL TYPE AND DIFFERENTIATION STATE ON REPROGRAMMING EFFICIENCY
The derivation of iPS cells remains an extremely inefficient process ranging from 0.01% to 0.1%. This low efficiency of iPS cell derivation may be due to rare cells within the starting population, which serve as selective cells of origin. For example, adult stem cells are present in many tissues at about the same frequency as the success rate of reprogramming. Consistent with this notion, NSCs have been suggested to give rise to iPS cells 30-50 times more efficiently than fibroblasts (Kim et al. 2008) , although another report came to different conclusions (Eminli et al. 2008) .
The identity of the starting cells that give rise to iPS cells remains controversial. Two recent experiments addressed the cell-of-origin question in different cellular systems and came to different conclusions. In the first set of experiments, Hanna et al. (2008) attempted reprogramming of B lymphocytes into iPS cells. B cells carry differentiation-associated DNA rearrangements, which serve as an unambiguous genetic marker for their differentiation state (Hochedlinger and Jaenisch 2002a) . Interestingly, ectopic expression of Oct4, Sox2, c-Myc, and Klf4 alone was insufficient to reprogram B lymphocytes into iPS cells, even when using a "secondary" system, in which most, if not all, cells express the four factors homogeneously (Maherali et al. 2008; Wernig et al. 2008a) . The authors had to either overexpress the transcription factor CEBPα or knock down its suppressed target gene Pax5 in addition to overexpressing the four factors to generate iPS cells from B cells. In contrast, progenitor B cells (pro-B cells) were permissive for reprogramming by the four factors alone, consistent with the notion that the differentiation state of the starting cell may affect reprogramming efficiency. Although this experiment indicated that defined terminally differentiated cells remain susceptible for reprogramming by defined factors, it is unclear, at this point, whether the difficulty in reprogramming lymphocytes is due to a biological barrier or merely reflects technical limitations.
In another set of experiments, Stadtfeld et al. (2008a) used genetically marked, terminally differentiated pancreatic β cells for reprogramming into iPS cells. β cells gave rise to iPS cells at a frequency comparable to fibroblasts (0.1-0.2%), demonstrating that this terminally differentiated cell type can be reprogrammed into iPS cells by just four factors and that adult stem cells are unlikely criteria are used to isolate iPS cells (Mikkelsen et al. 2008) . These cell lines show incomplete demethylation and reactivation of pluripotency genes (Takahashi and Yamanaka 2006; Mikkelsen et al. 2008 ). Interestingly, genome-wide expression analyses showed that partially reprogrammed cell lines derived from B cells and fibroblasts are more similar to one another than to their cells of origin, suggesting that there could be one or several common intermediate state(s) in which somatic cells get trapped, irrespective of the cell of origin (see Fig. 2 ) (Mikkelsen et al. 2008) .
Interestingly, partially reprogrammed cell lines show activation of lineage-specific genes not normally expressed in the starting cell population or in pluripotent cells (Mikkelsen et al. 2008) . Knockdown of these genes, combined with the treatment with a DNA methylation inhibitor, resulted in a more efficient transition from the partially to a fully reprogrammed state, which suggests that ectopic expression of lineage-specific transcription factors and hypermethylation may prevent conversion into a pluripotent state (Fig. 2) .
Although the analysis of partially reprogrammed cell states has been informative for understanding the "trapped" intermediate stages, a more detailed analysis of earlier and later stages of reprogramming will be critical for establishing the sequence of transcriptional and epigenetic events that lead to a pluripotent state. In attempts to define such early intermediates, two independent studies have shown that in vitro reprogramming of fibroblasts follows a defined sequence of molecular events, beginning with the down-regulation of somatic markers such as Thy1 and collagens, followed by the reactivation of the embryonic marker SSEA1 (Fig. 3) (Brambrink et al. 2008; Stadtfeld et al. 2008b ). SSEA1-positive cells then gradually reactivate other markers associated with pluripotency including Oct4, Sox2, Nanog, telomerase, and the silent X chromosome in female cells. Reactivation of these late markers correlates with the time window when cells become independent of viral transgene expression and enter a self-sustaining pluripotent state. Importantly, sort- the selective cell type in successful reprogramming experiments. There are several explanations for the different outcomes of reprogramming lymphocytes and β cells. First, lymphocytes belong to the mesodermal lineage, whereas β cells are derived from endoderm. Liver and stomach cells, which are also endodermal derivatives, have recently been shown to be more amenable to reprogramming (Aoi et al. 2008 ) than fibroblasts (mesoderm). Alternatively, β cells could be more easily reprogrammed than lymphocytes because the pancreas does not contain stem, progenitor, and differentiated cells, as seen in the hematopoietic system, but rather a pool of β cells that continuously replicate (Dor et al. 2004 ). It will undoubtedly be interesting to compare the reprogramming efficiencies between undifferentiated and fully differentiated cells within a given cell lineage, for example, in the hematopoietic system.
REPROGRAMMING AND INSERTIONAL MUTAGENESIS
Another possible explanation for the low efficiency of reprogramming is the potential requirement for insertional mutagenesis by the viral transgenes (Hawley 2008) . It has been previously shown that the retroviral infection of explanted blood stem cells selects for clones in which viruses inserted into genes conferring self-renewal to cells (Kustikova et al. 2005) . Similarly, one or several of the viral copies present in iPS cells could have integrated into and activated a gene(s) that facilitates the reacquisition of a pluripotent, self-renewing state. The sequencing of 34 viral insertion sites in iPS cells derived from liver and stomach cells did not reveal any common integration sites (Aoi et al. 2008) . However, sequencing has not yet been performed at saturation and it was still possible that insertional mutagenesis has a role during in vitro reprogramming (Hawley 2008) . To ultimately exclude the possibility that there may be "hidden" reprogramming genes that become activated or inactivated as a result of viral integration, iPS cells needed to be generated without any genetic manipulation, for example, by using small chemical compounds, direct protein transduction, or nonintegrating viruses. Indeed, we have recently generated iPS cells without integrating viruses by infecting tail fibroblasts and hepatocytes with adenoviruses transciently expressing Oct4, Sox4, Kef4, and c-Myc (Stadtfeld et al. 2008) .
A HIGH EFFICIENCY SYSTEM TO STUDY THE MECHANISMS OF DIRECT REPROGRAMMING
A third possibility for the low efficiency of reprogramming is the idea that the factors can only achieve reprogramming when expressed in precise relative amounts. Fibroblast-derived iPS cells carry on average 10-20 proviral transgenes expressing Oct4, Sox2, Klf4, and cMyc, and the four transgenes are found at different copy numbers per cell (Takahashi and Yamanaka 2006; Maherali et al. 2007; Wernig et al. 2007; Eminli et al. 2008) , suggesting that stoichiometry may be important. This is consistent with observations in ES cells, where the levels of Oct4 and Sox2 are critical for maintaining a selfrenewing pluripotent state (Niwa et al. 2000; Kopp et al. 2008) . In further agreement, the reprogramming of Sox2-expressing NSCs into iPS cells in the absence of exogenous Sox2 expression results in an approximately fourfold increase in overall efficiency (Eminli et al. 2008) . Thus, it is conceivable that the frequency at which a single somatic cell receives the four viral transgenes at the appropriate stoichiometry is extremely low.
If viral infection is indeed the rate-limiting step, one would predict that cells that can reactivate all four factors at the correct stoichiometry should give rise to iPS cells at an efficiency close to 100%. To address this question, we generated differentiated fibroblast-like "secondary" cells from human-induced pluripotent stem (hiPS) cells produced with doxycycline-inducible viral transgenes (Fig. 4) (Maherali et al. 2008) . In these cells, most of the cells express the four factors together and likely at the correct stoichiometry upon exposure to doxycycline. Indeed, secondary hiPS cells were obtained up to 100 times more efficiently compared with iPS cells produced by direct viral infection, indicating that viral infection and the correct stoichiometry of the four factors are parameters that limit reprogramming efficiency. Experiments with mouse cells came to similar conclusions Wernig et al. 2008a ). However, the overall efficiency was still quite low in all of these experiments (1-3% for secondary cells compared with 0.01-0.1% for primary infected cells), suggesting that additional events need to take place in order to reprogram somatic cells to pluripotency. These events likely involve stochastic epigenetic alterations including changes in DNA and histone methylation. Consistent with this notion, the treatment of somatic cells with compounds that inhibit DNA or histone methylation or histone deacetylation enhances the recovery of iPS cells significantly Huangfu et al. 2008; Shi et al. 2008) . 
CONCLUSIONS
The study of induced pluripotency by defined transcription factors has yielded some important insights into the mechanisms underlying epigenetic reprogramming. Moreover, it has facilitated the derivation of patient-specific iPS cells from a variety of diseases (Dimos et al. 2008; Park et al. 2008a ) to establish in vitro models for these disorders (Fig. 5) . A major challenge before translating iPS technology into a therapeutic setting will be to induce pluripotency without genetic manipulation. Another open question is whether iPS cells are truly identical to ES cells or whether they retain a molecular memory of their cell of origin, as has been seen in some NT experiments (Hochedlinger and Jaenisch 2003) . Finally, iPS technology has sparked interest in attempts to trans-differentiate specialized cells directly into other types of specialized cells by using alternative sets of transcription factors, for example from fibroblasts into myogenic cells (Davis et al. 1987) , B lymphocytes into macrophages (Xie et al. 2004) , or pancreatic exocrine cells into insulin-producing cells (Zhou et al. 2008) . The next few years will undoubtedly bring exciting new discoveries on the role of transcription factors in cellular differentiation and epigenetic reprogramming. Reprogramming by nuclear transfer, cell fusion, or defined factors may allow for the generation of patient-specific pluripotent cell lines. Pluripotent cells could be differentiated in vitro into the desired cell types and then transplanted into patients (cell therapy approach) or, alternatively, be used to establish in vitro models of diseases for drug screens and toxicology testing (disease modeling approach).
